We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
26
DELISTED
SpringWorks Therapeutics
SWTX
$16.1M 1.09%
195,117
+57,445
+42% +$4.36M
FATE icon
27
Fate Therapeutics
FATE
$286M
$14.3M 0.97%
165,299
+55,492
+51% +$4.47M
LPSN icon
28
LivePerson
LPSN
$21.8M
$14.2M 0.96%
15,000
-2,333
-13% -$1.97M
AMZN icon
29
Amazon
AMZN
$2.92T
$14M 0.94%
81,220
+26,000
+47% +$4.32M
PTGX icon
30
Protagonist Therapeutics
PTGX
$8.79B
$13.6M 0.92%
302,965
+100,831
+50% +$3.33M
VTGN icon
31
VistaGen Therapeutics
VTGN
$9.89M
$12.9M 0.87%
136,022
-3,217
-2% -$238K
AUDC icon
32
AudioCodes
AUDC
$244M
$12.7M 0.86%
385,194
-90,430
-19% -$2.89M
KYMR icon
33
Kymera Therapeutics
KYMR
$8.51B
$12.6M 0.85%
259,895
+12,368
+5% +$537K
VRNS icon
34
Varonis Systems
VRNS
$4.59B
$12.6M 0.85%
218,013
+79,338
+57% +$4.13M
ONCR
35
DELISTED
Oncorus, Inc.
ONCR
$12.3M 0.83%
893,548
-9,563
-1% -$148K
HOWL icon
36
Werewolf Therapeutics
HOWL
$17.2M
$12M 0.82%
+706,294
New +$9.68M
CRNX icon
37
Crinetics Pharmaceuticals
CRNX
$8.84B
$12M 0.81%
634,088
+349,864
+123% +$6.15M
AFMD
38
DELISTED
Affimed
AFMD
$10.9M 0.73%
127,670
+25,773
+25% +$2.35M
ALXO icon
39
ALX Oncology
ALXO
$261M
$10.5M 0.71%
192,728
+62,377
+48% +$3.73M
TWLO icon
40
Twilio
TWLO
$30B
$10.4M 0.71%
+26,500
New +$9.2M
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$10.4M 0.7%
1,009,497
+289,497
+40% +$2.94M
IOVA icon
42
Iovance Biotherapeutics
IOVA
$1.82B
$9.85M 0.67%
+378,642
New +$9.84M
CSTE icon
43
Caesarstone
CSTE
$72.3M
$9.51M 0.64%
644,146
+108,998
+20% +$1.65M
SNDX icon
44
Syndax Pharmaceuticals
SNDX
$1.69B
$9.39M 0.64%
547,187
-90,906
-14% -$1.67M
META icon
45
Meta Platforms (Facebook)
META
$1.42T
$9.39M 0.64%
+27,000
New +$8.66M
SEDG icon
46
SolarEdge
SEDG
$2.51B
$8.9M 0.6%
+32,200
New +$8.11M
NTLA icon
47
Intellia Therapeutics
NTLA
$1.49B
$8.51M 0.58%
+52,550
New +$4.09M
BIIB icon
48
Biogen
BIIB
$30B
$8.31M 0.56%
23,995
+17,195
+253% +$5.21M
TEVA icon
49
Teva Pharmaceuticals
TEVA
$40.8B
$8.24M 0.56%
832,878
– –
NAUT icon
50
Nautilus Biotechnolgy
NAUT
$124M
$8.08M 0.55%
800,000
+400,000
+100% +$4.33M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.